Patient characteristics
| . | DR . | DE . | P value∗ . |
|---|---|---|---|
| n | 30 | 65 | |
| Median age at CLL diagnosis (IQR), y | 57 (49-63) | 58 (52-64) | .5 |
| Male, n (%) | 22 (73.3) | 42 (64.6) | .4 |
| IGHV, n (%) | .12† | ||
| Mutated | 1 (3.3) | 9 (13.8) | |
| Unmutated | 29 (96.7) | 49 (75.4) | |
| Unknown | 0 (0.0) | 7 (10.8) | .2‡ |
| Hierarchical FISH category, n (%) | .49§ | ||
| Deletion 17p | 12 (40.0) | 18 (27.7) | .23|| |
| Deletion 11q | 3 (10.0) | 13 (20.0) | |
| Trisomy 12 | 4 (13.3) | 6 (9.2) | |
| Normal | 8 (26.7) | 14 (21.5) | |
| Deletion 13q | 3 (10.0) | 13 (20.0) | |
| Unknown | 0 (0.0) | 1 (1.5) | |
| Karyotype | |||
| Data available, n (%) | 26 (86.7) | 55 (84.6) | |
| No. of abnormalities, median (range) | 5 (0-22) | 3 (0-17) | |
| ≥3 abnormalities, n (% evaluable) | 20 (76.9) | 31 (56.4) | .07 |
| ≥5 abnormalities, n (% evaluable) | 15 (57.7) | 21 (38.2) | .10 |
| . | DR . | DE . | P value∗ . |
|---|---|---|---|
| n | 30 | 65 | |
| Median age at CLL diagnosis (IQR), y | 57 (49-63) | 58 (52-64) | .5 |
| Male, n (%) | 22 (73.3) | 42 (64.6) | .4 |
| IGHV, n (%) | .12† | ||
| Mutated | 1 (3.3) | 9 (13.8) | |
| Unmutated | 29 (96.7) | 49 (75.4) | |
| Unknown | 0 (0.0) | 7 (10.8) | .2‡ |
| Hierarchical FISH category, n (%) | .49§ | ||
| Deletion 17p | 12 (40.0) | 18 (27.7) | .23|| |
| Deletion 11q | 3 (10.0) | 13 (20.0) | |
| Trisomy 12 | 4 (13.3) | 6 (9.2) | |
| Normal | 8 (26.7) | 14 (21.5) | |
| Deletion 13q | 3 (10.0) | 13 (20.0) | |
| Unknown | 0 (0.0) | 1 (1.5) | |
| Karyotype | |||
| Data available, n (%) | 26 (86.7) | 55 (84.6) | |
| No. of abnormalities, median (range) | 5 (0-22) | 3 (0-17) | |
| ≥3 abnormalities, n (% evaluable) | 20 (76.9) | 31 (56.4) | .07 |
| ≥5 abnormalities, n (% evaluable) | 15 (57.7) | 21 (38.2) | .10 |
Shown here are the results of the initial FISH and karyotype data tested for each patient. IGHV mutation status was assessed once at any time point during the disease course.
IQR, interquartile range.
Wilcoxon rank-sum test and Pearson χ2 test were used to compare continuous and categorical variables; Fisher exact test was used when sample size was small and had cell counts <5, respectively, between DR and DE patients.
For overall comparison across all IGHV status categories between DR and DE patients.
For specific comparison between the unmutated group vs mutated group between DR and DE patients.
For overall comparison across all hierarchical FISH categories between DR and DE patients.
For specific comparison between the deletion 17p group vs the combined group of all other categories between DR and DE patients.